Nephrology & urology
Kidney & urinary clinical trials
Kidney disease and conditions of the bladder and urinary tract. We’re tracking 4,391 recruiting studies in this area right now.
By phase
- Not applicable2,721
- Phase 2568
- Phase 1363
- Phase 3265
- Phase 1/Phase 2227
- Phase 4192
- Phase 2/Phase 355
Top conditions
- Prostate Cancer645
- Bladder Cancer186
- Acute Kidney Injury134
- Chronic Kidney Diseases122
- Chronic Kidney Disease107
- Breast Cancer104
- Renal Cell Carcinoma80
- Urinary Incontinence60
- Kidney Cancer59
- Colorectal Cancer58
- Ovarian Cancer56
- Lung Cancer51
- Cancer48
- Lupus Nephritis48
- Melanoma47
- Head and Neck Cancer46
- Metastatic Prostate Cancer46
- Hypertension45
Leading sponsors
- Mayo Clinic64
- National Cancer Institute (NCI)48
- Peking University First Hospital39
- M.D. Anderson Cancer Center36
- Chinese University of Hong Kong35
- Novartis Pharmaceuticals33
- AstraZeneca29
- IRCCS Azienda Ospedaliero-Universitaria di Bologna29
- Memorial Sloan Kettering Cancer Center29
- Assistance Publique - Hôpitaux de Paris27
Where studies are running
- California358
- Arizona109
- Alabama107
- New York96
- Florida93
- Maryland91
- Texas91
- Massachusetts88
- Illinois66
- Minnesota50
Recruiting studies4,391 total
- NCT05790213RecruitingPhase 2
Hormone therapy plus targeted prostate treatment for intermediate cancer
This Phase 2 study tests whether combining hormone treatment (androgen deprivation therapy) with focal ablation (targeted destruction of prostate tissue) controls intermediate-risk prostate cancer. It may help some men avoid or reduce more aggressive treatment, while still aiming for cancer control.
Chicago, IllinoisAges 18 years+ - NCT05805371RecruitingPhase 1
PSCA CAR-T cells with or without radiation for prostate cancer
This Phase 1 study tests a prostate cancer treatment made of PSCA-targeted CAR-T cells, with or without radiation, to help control advanced prostate cancer. It aims to find a safe treatment approach and see how well it works in people whose cancer has PSCA.
Duarte, CaliforniaAges 18 years+ - NCT05810467Recruiting
Active surveillance study for men at higher risk prostate cancer
This trial studies how well “active surveillance” works for men with prostate cancer who are considered higher risk because of family history or genetics. It aims to safely monitor the cancer and decide the best timing for treatment if needed, while tracking side effects and follow-up success.
Sutton, SurreyAges 18 years+ - NCT05793138Enrolling by invitation
Care model for older adults on dialysis at home
This trial tests a geriatric (older-adult) care approach to support people age 55+ who receive dialysis while living in the community. It may help improve how care is coordinated for older adults, including those with mild to moderate memory or thinking problems.
Durham, North CarolinaAges 55 years+ - NCT05805709Recruiting
COPE-AKI: A care plan for people hospitalized with serious AKI
This trial tests a patient-centered plan for how care is organized and communicated for people hospitalized with serious, persistent kidney injury (AKI). The goal is to improve the experience and possibly outcomes by making care more consistent and easier to follow.
Birmingham, AlabamaAges 18 years+ - NCT05786443RecruitingPhase 2
Empagliflozin test in adults on regular dialysis
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
Boston, MassachusettsAges 18 years+ - NCT05782543Recruiting
Testing improved kidney repair outside the body during transplant
This trial tests a machine method that keeps a donated kidney working “outside the body” so it may be better repaired before transplant. It is designed for certain first/second kidney transplants using specific donor types and storage methods.
Groningen, Provincie GroningenAges 50–100 - NCT05786716RecruitingPhase 2/Phase 3
Trastuzumab plus pertuzumab for HER2-mutated cancers
This trial tests whether combining trastuzumab and pertuzumab can treat cancers that have HER2 amplification or an activating HER2 mutation. It looks at people ages 12 and older, and may include both children/teens and adults, using the study drug based on their HER2 test results.
BelfastAges 12 years+ - NCT05779631Recruiting
MRI test to better stage suspected bladder cancer
This study uses a special MRI scan (mpMRI) to figure out how far suspected muscle-invasive bladder cancer has spread, using a new local staging approach. If the results are accurate, it may help doctors plan the most appropriate curative treatment sooner.
's-HertogenboschAges 18 years+ - NCT05806645Recruiting
Digital tools to guide recovery after a kidney injury
This study uses personalized risk information and digital tools to help people plan safe transitions after a recent hospital kidney injury. The goal is to better guide next steps and reduce the chance of future kidney problems.
Calgary, AlbertaAges 18 years+ - NCT05800665RecruitingPhase 1
Study tests a new prostate cancer drug after prior hormone therapy
This Phase 1 study tests the safety, how the drug moves through the body, and whether it shows anti-cancer activity in men with advanced or metastatic prostate cancer. It is designed for people whose cancer has already been treated with certain hormone (androgen receptor) therapies.
Scottsdale, ArizonaAges 18 years+ - NCT05804318Recruiting
Adaptive daily radiation for low- and intermediate-risk prostate cancer
This trial tests a radiation plan that is adjusted every day using your own scans to better target prostate cancer. It may help reduce side effects while still treating the cancer effectively in men with lower- or intermediate-risk disease.
Duarte, CaliforniaAges 18 years+ - NCT05803941RecruitingPhase 4
Study long-term safety of a prostate cancer drug
This trial checks the long-term safety (how it affects you over time) of lutetium-177 vipivotide tetraxetan in people with prostate cancer. You may be eligible if you already received the related drug in a prior Novartis prostate cancer study and can complete the required follow-up tests.
Scottsdale, ArizonaAges 18–100 - NCT05795140RecruitingPhase 3
Long-term safety study of iptacopan for aHUS
This study follows people with aHUS who are already taking iptacopan to check how well it continues to work and how safe it is over the long term. You may be asked to keep taking the study medicine and follow extra safety rules, including infection and pregnancy precautions.
São Paulo, São PauloAges 18–100 - NCT05785039RecruitingPhase 2
Study drug for advanced bladder and other solid cancers
This Phase 2 trial tests BL-B01D1 to treat people with advanced or metastatic urothelial (urinary tract) cancer and other solid tumors. You may be eligible if standard treatments are no longer working or are not available, and you can meet safety and cancer-measurement requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05387863Recruiting
Decision aid for people with small kidney tumors
This trial tests a decision aid—a simple guide—to help kidney cancer patients understand options and make choices with their urology team. It may help you feel more informed and confident before or after your kidney procedure.
New York, New YorkAges 18 years+ - NCT05753930RecruitingPhase 2
New medicine to help highly sensitised children receive kidney transplants
This trial tests a new medicine called imlifidase that quickly removes harmful antibodies from the blood. It is given to children before a kidney transplant to make the donated kidney more likely to be accepted, especially when standard desensitisation methods have failed.
HelsinkiAges 1–17 - NCT05759923RecruitingPhase 1
Study of OATD-02 for hard-to-treat solid tumors
This early (first-in-human) study tests whether OATD-02 is safe and tolerable, and whether it shows any anti-cancer activity. It is for adults with certain advanced or metastatic cancers that have already been treated with the standard options.
Bydgoszcz, Kuyavian-Pomeranian VoivodeshipAges 18 years+ - NCT05758077Recruiting
SeLective blood-filter trial for acute kidney injury in ICU
This trial tests a special device that filters parts of the blood to calm inflammation in people with severe acute kidney injury in the ICU. It may help improve recovery and reduce complications by “deactivating” certain immune cells.
Birmingham, AlabamaAges 18 years+ - NCT05755386RecruitingPhase 3
Iptacopan for idiopathic IC-MPGN with heavy protein in urine
This trial tests iptacopan (an add-on medicine) in people with idiopathic immune-complex membranoproliferative glomerulonephritis (IC-MPGN), a kidney disease causing significant protein loss in urine. It aims to improve kidney outcomes and safety when added to standard treatments.
Los Angeles, CaliforniaAges 12–60 - NCT05766371RecruitingPhase 2
Immunotherapy plus targeted radiation for advanced prostate cancer
This study combines two treatments: pembrolizumab, which helps your immune system fight cancer, and a targeted radioactive medicine (177Lu-PSMA-617) that seeks out and damages prostate cancer cells. It may help men whose prostate cancer has spread despite initial hormone therapy.
San Francisco, CaliforniaAges 18 years+ - NCT05775614Enrolling by invitation
Catheter care rinse study to prevent infections and improve comfort
This study tests a catheter “rinse” product (UroTainer) or plain saline to help keep a permanent catheter working and reduce infection risk. It also looks at comfort and quality of life for people who have had catheter problems like blockage or buildup.
OdenseAges 18 years+ - NCT05762536RecruitingPhase 2
Docetaxel or cabazitaxel with or without darolutamide
This Phase 2 study tests whether adding darolutamide to either docetaxel or cabazitaxel helps treat men with advanced, progressing prostate cancer. It’s for cancers that have already grown despite hormone-blocking tablets (ARSi).
RotterdamAges 18 years+ - NCT05751434RecruitingPhase 2
Exercise therapy for prostate cancer patients on active surveillance
This trial tests whether an exercise program can help men with early-stage prostate cancer who are being monitored instead of treated. If you are not very active now, you may be able to join a structured exercise plan to see if it improves your health and cancer signs.
Durate, CaliforniaAges 18 years+
Common questions
- How many kidney & urinary clinical trials are recruiting?
- Clin2 is tracking 4,391 recruiting nephrology & urology studies from the U.S. registry right now, out of 6,874 we cover in this area in total.
- What does “Kidney & urinary” cover here?
- Kidney disease and conditions of the bladder and urinary tract. We group each study into kidney & urinary based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a kidney & urinary trial near me?
- Use the search to filter kidney & urinary studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.